Jeito Capital
Venture capital
RollingLast verified 7 Nov 2026
Jeito Capital is a Paris-based venture capital firm investing in ground-breaking medical innovation and biotech companies across Europe and the United States.
2 deals in the last 24 months, latest 14 Apr 2026. From its website and its deals in the news.
Key facts
- Stages
- Series A, Series B, Series C+
- Sectors
- Biotech & pharma
- Eligible countries
- Not stated
- Provider based in
- France
- Timing
- Rolling applications
- Focus
- medical innovation; biotech; therapeutics
- How to apply
- Apply route unknown
- Source
- https://jeito.life/
Recent deals
| Company | Round | Sectors | Amount | Role | Announced |
|---|---|---|---|---|---|
| Adcendo ApS | Series C+ | Biotech & pharma, Healthtech | €67.2M | lead | 14 Apr 2026 |
| Azafaros | Series B | Biotech & pharma, Healthtech | €132M | lead | 13 May 2025 |
Funds
- Jeito II Fund · €1B · closed 8 Apr 2026
Evidence
Short excerpts from the sources, in their original language, that back the facts above.
- Kind
Jeito Capital is a global leading investment company with a patient benefit driven approach that finances and accelerates ground-breaking medical innovation.
https://jeito.life/ - Sectors
Jeito is the fact they’ve got functional experts on board in each of the critical areas for a biotech company
https://jeito.life/ - Stages
Jeito Capital co-leads a $165 million oversubscribed Series A financing in Bionyra Pharma
https://jeito.life/
Status history
- 7 Nov 2026: Uncertain → Rolling (freshness: investor activity)
- 6 Nov 2026: Uncertain (first extraction)
Something wrong or out of date? Report an error.
Work at Jeito Capital? Claim this profile to confirm what you invest in.